A Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT01990534)
This phase IV, single-arm, open-label, multicenter study is designed to evaluate the efficacy and safety of brentuximab vedotin (also known as SGN-035) as a single agent in adult patients with histologically confirmed CD30+ relapsed or refractory classical Hodgkin lymphoma (HL) who have not received a prior stem cell transplantation (SCT) and are considered to be not suitable for SCT or multiagent chemotherapy at the time of study entry.
This trial is sponsored by Millennium Pharmaceuticals. 
- Condition: Lymphoma
- Drugs used in this trial
- Phase: IV
- Estimated Enrollment: 60
- Start: March 2014
- Estimated Completion: December 2019
- Last verified: April 2015
Last Editorial review: July 21, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.